OraPharma, a division of Bausch Health US, LLC
$539.1K 7,610 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Pulse Biosciences, Inc.
Pulse Biosciences, Inc. reported $534,821.47 across General Payments, Research, and Ownership to 72 physicians and teaching hospitals across 72 transactions.
- $534.8K
- All-tracks total
- 72
- Transactions
- 72
- Recipients
- #745
- of 1,925 companies
Pulse Biosciences, Inc. reported $534,821.47 across all CMS Open Payments tracks (General + Research + Ownership) to 72 physicians and teaching hospitals in Program Year 2024 - ranking #745 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $534,821.47, averaging $7.4K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pulse-biosciences-inc Pulse Biosciences, Inc.
$534.8K · #745/1,925 · 0.0% industry · PY2024
- TOT $534.8K
- RANK #745
- SHARE 0.0%
- TXN 72
- RCP 72
- CAT 4
- GEN $534.8K
- TOP1 25.6%
- PY 2024
Volume peers
Nearest volume peer: OraPharma, a division of Bausch Health US, LLC ($539.1K)
Pulse Biosciences, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Pulse Biosciences, Inc.
$534,821.47: that is what Pulse Biosciences, Inc. reported in payments to 72 physicians and teaching hospitals during Program Year 2024, spread across 72 transactions ($7.4K per transaction, $7.4K per recipient). The company sits at rank #745 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
"Consulting Fee" leads the 4-category general-payment breakdown below at $377.2K (70.5% of General Payments, 38 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads Pulse Biosciences, Inc.'s 4-category general-payment breakdown at $377.2K, 70.5% of the reported total.
Pulse Biosciences, Inc. reports 4 general-payment categories - the top three are Consulting Fee (70.5%), Long-Term Medical Supply or Device Loan (21.5%), and Travel and Lodging (7.6%). The remaining 1 category make up 0.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Pulse Biosciences, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $377.2K | 38 | 70.5% |
| Long-Term Medical Supply or Device Loan | $115.0K | 16 | 21.5% |
| Travel and Lodging | $40.7K | 4 | 7.6% |
| Food and Beverage | $2.0K | 14 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $449,325.50 (84.0%) of $534,821.47 in this company's General Payments records across 19 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pulse Biosciences, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Gansevoort Hurlbut Dunningtion
$137,102.67 across 12 reported transactions
- 2
Niv Ad
$130,891.53 across 10 reported transactions
- 3
David Noah Kenigsberg
$80,977.20 across 6 reported transactions
- 4
Ralph P. Tufano
$71,177.05 across 11 reported transactions
- 5
Richard J Harding
$29,177.05 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Pulse Biosciences, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Pulse Biosciences, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Pulse Biosciences, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Dynavax Technologies Corporation
$530.5K 5,747 recipients
Compare payment profiles
OraSure Technologies Inc.
$529.4K 45 recipients
Compare payment profiles
Veryan Medical Incorporated
$525.9K 278 recipients
Compare payment profiles
GC America Inc.
$524.2K 2,479 recipients
Compare payment profiles
Zynex Monitoring Solutions
$546.3K 0 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.